Rheumatic Disorders

New classification criteria for systemic sclerosis have been developed and should allow for more patients to be classified as having systemic sclerosis compared with the 1980 criteria, said Janet E. Pope, MD, MPH, FRCPC, Professor of Medicine and Division Head of Rheumatology at St Joseph’s Hospital and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada. By Wayne Kuznar
By David Hawk Berlin, Germany—A multidisciplinary task force formed under the aegis of the European League Against Rheumatism (EULAR) has for the first time developed recommendations for the management of medium-to-high-dose systemic glucocorticoid therapy in rheumatic diseases.
By Neil Canavan Berlin, Germany—Data from 2 separate studies presented at the 2012 European League Against Rheuma­tism Congress led researchers to the same conclusion: successful treatment of patients with rheumatic diseases with anti–tumor necrosis factor (TNF) drugs and/or nonbiologic disease-modifying antirheumatic drugs (DMARDs) lowers the risk for early mortality compared with patients who do not respond well to treatment.
By Wayne Kuznar Routine screening for replicating JC polyomavirus (JCPyV) or serum antibodies does not seem to be warranted in rheumatic patients treated with rituximab (Rituxan).

Results 1 - 4 of 4
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology